A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies
← catalyst calendarSponsored by Erasca, Inc. (industry) · ERAS — their whole pipeline →.
Phase
Phase 1/2
Status
Withdrawn
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
0actual
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decision.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-15 | estimated | When the study began enrolling |
| Primary completion | 2025-03-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-01 | estimated | The whole study's end, after follow-up |
| First posted | 2022-03-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2022-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acute Myeloid Leukemia
Interventions
- Drug: ERAS-007
- Drug: ERAS-601
- Drug: Gilteritinib — also filed as Xospata
Primary outcomes
what the primary-completion date above is the date OFDose Limiting Toxicities (DLT)
measured Study Day 1 up to Day 29
Maximum Tolerated Dose (MTD)
measured Study Day 1 up to Day 29
Recommended Dose (RD)
measured Study Day 1 up to Day 29
Adverse Events
measured Assessed up to 24 months from time of first dose
Permalink · ERAS's whole pipeline · Catalyst calendar · Every registered study · What changed